Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sergey Shcherbinin

Showing results (31-40 of 74) with videos related to

Pageof 8
Sort By:
Alzheimer'S Research & Therapy|October 7, 2025
Regional tau PET patterns predict prospective domain-specific cognitive decline in early symptomatic Alzheimer's diseaseMaura Malpetti, Saima Rathore, Leonardo Iaccarino, et al.
JAMA Neurology|October 17, 2022
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical TrialMichael J Pontecorvo, Ming Lu, Samantha C Burnham, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|August 3, 2014
Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancersMirosław L Nowicki, Jarosław B Cwikla, Artur J Sankowski, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2025
Donanemab exposure-response in early symptomatic Alzheimer's diseaseIvelina Gueorguieva, Kay Chow, Laiyi Chua, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2010
Incorporating quantitative single photon emission computed tomography into radiation therapy treatment planning for lung cancer: impact of attenuation and scatter correction on the single photon emission computed tomography-weighted mean dose and functional lung segmentationLingshu Yin, Sergey Shcherbinin, Anna Celler, et al.
Plos Computational Biology|March 14, 2009
Detection of alpha-rod protein repeats using a neural network and application to huntingtinGareth A Palidwor, Sergey Shcherbinin, Matthew R Huska, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 16, 2025
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3Roy Yaari, Karen C Holdridge, Melissa Williamson, et al.
JAMA Neurology|October 13, 2025
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical TrialMing Lu, Min Jung Kim, Emily C Collins, et al.
Journal of Alzheimer'S Disease Reports|October 18, 2023
Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical TrialBrian A Willis, Albert C Lo, Jeffrey L Dage, et al.
JAMA Neurology|November 6, 2023
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid LevelsAnna Steward, Davina Biel, Anna Dewenter, et al.
Pageof 8

Showing results (31-40 of 74) with videos related to

Sort By:
Pageof 8
Alzheimer'S Research & Therapy|October 7, 2025
Regional tau PET patterns predict prospective domain-specific cognitive decline in early symptomatic Alzheimer's diseaseMaura Malpetti, Saima Rathore, Leonardo Iaccarino, et al.
JAMA Neurology|October 17, 2022
Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical TrialMichael J Pontecorvo, Ming Lu, Samantha C Burnham, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|August 3, 2014
Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancersMirosław L Nowicki, Jarosław B Cwikla, Artur J Sankowski, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2025
Donanemab exposure-response in early symptomatic Alzheimer's diseaseIvelina Gueorguieva, Kay Chow, Laiyi Chua, et al.
International Journal of Radiation Oncology, Biology, Physics|May 11, 2010
Incorporating quantitative single photon emission computed tomography into radiation therapy treatment planning for lung cancer: impact of attenuation and scatter correction on the single photon emission computed tomography-weighted mean dose and functional lung segmentationLingshu Yin, Sergey Shcherbinin, Anna Celler, et al.
Plos Computational Biology|March 14, 2009
Detection of alpha-rod protein repeats using a neural network and application to huntingtinGareth A Palidwor, Sergey Shcherbinin, Matthew R Huska, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 16, 2025
Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3Roy Yaari, Karen C Holdridge, Melissa Williamson, et al.
JAMA Neurology|October 13, 2025
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical TrialMing Lu, Min Jung Kim, Emily C Collins, et al.
Journal of Alzheimer'S Disease Reports|October 18, 2023
Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer's Disease: A Phase I Clinical TrialBrian A Willis, Albert C Lo, Jeffrey L Dage, et al.
JAMA Neurology|November 6, 2023
ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid LevelsAnna Steward, Davina Biel, Anna Dewenter, et al.
Pageof 8